Advanced blood cancer trial with stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer like acute leukemia or myelodysplastic syndrome that is in remission or has low blast counts.
- You are between 18 and 70 years old.
- You are healthy enough for a strong conditioning regimen before transplant, like total body irradiation or chemotherapy.
- You have a related or unrelated donor who matches at 7 out of 8 key HLA markers.
- Your kidney, heart, and lung function are within acceptable ranges.
- You have not had a prior stem cell transplant and are not on immune-suppressing drugs like high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
This study tests a new way to give donor stem cells (called Orca-T) after a special type of chemotherapy and radiation. It is for people aged 60–75 with certain blood cancers that have not responded well to standard treatments.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.